Joint Assessments
As of March 2016, EUnetHTA has finalised 20 joint assessments: 2 joint assessments during EUnetHTA Project (2006-2008), 3 joint assessments during EUnetHTA JA (2010-2012) and 15 joint assessments during EUnetHTA JA2 (2012-2015).
EUnetHTA JA3 (2016-2020)
Overview Table of Ongoing and Published Assessments
JA3 Rapid Relative Effectiveness Assessment (REA) of pharmaceutical technologies
Published Joint Assessments
Midostaurin with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia
JA3 Rapid Relative Effectiveness Assessment (REA) of other technologies
Ongoing Collaborative Assessments
Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) comapred to standard ultrasound phacoemulsification cataract surgery
Published Collaborative Assessments
Screening of fetal aneuplodies whereby non-invasive prenatal test (NIPT)
Repetitive transcranial magnetic stimulation for treatment-resistant major depression
EUnetHTA JA2 (2012-2015)
JA2 Full/Comprehensive assessments
Structured telephone support (STS) for adult patients with chronic heart failure. (Core HTA 3)
JA2 Rapid Relative Effectiveness Assessment (REA) of Pharmaceuticals
Canagliflozin for the treatment of type 2 Diabetes Mellitus
Zostavax for the prevention of Herpes Zoster and postherpetic Neuralgia
JA2 Rapid Relative Effectiveness Assessment (REA) of other Technologies
Balloon Eustachian tuboplasty for the treatment of Eustachian tube dysfunction
Biodegradable stents for the treatment of refractory or recurrent benign Oesophageal Stenosis
Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke
Renal denervation systems for treatment-resistant hypertension
EUnetHTA JA1 (2010 - 2012)
WP5 JA1 Pilot Pazopanib Report+Appendix
Abdominal Aorta Aneurysm Screening (AAA)
Prognostic tests for breast cancer recurrence (PTBCR)